ra-BEP-ra-zole 
Absorption: Delayed-release tablet is designed to allow rabeprazole, which is not stable in gastric acid, to pass through the stomach intact. Subsequently 52% is absorbed after oral administration.
Distribution: Unknown.
Protein Binding: 96.3%.
Metabolism/Excretion: Mostly metabolized by the CYP3A4 and CYP2C19 isoenzymes in the liver; (the CYP2C19 enzyme system exhibits genetic polymorphism; 15–20% of Asian patients and 3–5% of Caucasian and Black patients may be poor metabolizers and may have significantly ↑ rabeprazole concentrations and an ↑ risk of adverse effects); 10% excreted in feces; remainder excreted in urine as inactive metabolites.
Half-life: 1–2 hr.
Contraindicated in:
Use Cautiously in:
Derm: cutaneous lupus erythematosus, photosensitivity, rash.
F and E: hypomagnesemia (especially if treatment duration 
3 mo).
GI: CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), abdominal pain, constipation, diarrhea, fundic gland polyps, nausea.
GU: acute tubulointerstitial nephritis.
Hemat: vitamin B12 deficiency.
MS: bone fracture, neck pain.
Neuro: dizziness, headache, malaise.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS, ANGIOEDEMA, OR TUBULOINTERSTITIAL NEPHRITIS), chills, fever, systemic lupus erythematosus.
Drug-Drug:
Gastroesophageal Reflux Disease
12 yr): Short-term treatment of symptomatic GERD — 20 mg once daily for up to 8 wk.15 kg — 10 mg once daily for up to 12 wk (given as sprinkle); <15 kg — 5 mg once daily for up to 12 wk (given as sprinkle); may ↑ up to 10 mg once daily if inadequate response.Duodenal Ulcers
H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence (Triple Therapy)
Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
Aciphex, Aciphex Sprinkle
(Generic available)
(acid suppression)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | within 1 hr | unknown | 24 hr† |
†Suppression continues to increase over the first wk of therapy.
NDC Code*